One of the most eective ways to kill cancer cells is by treatment of tumours with radiation. However, the administered dose of radiation to the tumour is limited by normal tissue toxicity. Strategies which decrease normal tissue exposure relative to tumour dose are urgently sought. One such promising scheme involves gene transfer, leading to the introduction of transporters speci®c for pharmaceuticals which can be labelled with radionuclides. We have previously demonstrated in vitro, that transfer of the noradrenaline transporter (NAT) gene, under viral promoter control, induces in host cells the active accumulation of the radiopharmaceutical [ Telomerase counteracts the loss of DNA which occurs during replication by catalysing the addition of nucleotide repeats to telomeres. Cells which lack telomerase activity, sustain shortening of chromosomes resulting in senescence (Harley et al., 1990; Hastie et al., 1990) . Approximately 90% of human cancers possess active telomerase, whereas normal somatic tissues have either a much lower telomerase levels than tumours or have no detectable activity according to PCR-based assays (Kim et al., 1994; Broccoli et al., 1995; Harle-Bachor and Boukamp, 1996; Tahara et al., 1999) . Human telomerase activity depends upon the presence of both the RNA subunit (hTR) and the catalytic protein component hTERT . Recent studies have indicated that while the hTERT gene is expressed at low levels in cancer cells and is virtually undetectable in normal cells Kolquist et al., 1998) , the hTR gene can be expressed at high levels in tumour cells but can also be detected at low levels in normal tissues. This suggests that in some settings, telomerase could be a highly selective target for anti-cancer drugs.
Numerous studies have been performed to assess the potential therapeutic gain to be derived from inhibiting telomerase in tumour cells. These have employed agents which target telomerase directly, telomeric DNA and regulatory proteins acting at the level of telomerase or telomere (reviewed by Lavelle et al., 2000) . However, it is probable that anti-telomerase compounds would not be immediately cytotoxic because several replicative cycles would have to occur before telomere erosion became severe enough to trigger senescence. Furthermore, it has recently been documented that some tumour cells have the capacity to maintain telomeres despite the absence of telomerase expression (Bryan et al., 1997) . Such tumour cells may be resistant to anti-telomerase treatment. These potential limitations to telomerase-directed, cancer treatment prompt the exploration of alternative schemes which exploit the tumour cell speci®city of expression of the telomerase gene and result not only in rapid kill of telomerase-positive clonogens but also in toxicity to neighbouring malignant cells which have evolved telomerase-independent means of maintenance of telomeres.
Targeted radiotherapy is a promising approach to cancer treatment which seeks to minimize normal tissue damage by the selective concentration in malignant cells of tumour-seeking radiolabelled agents (Wheldon, 2000 Kraker et al., 1995; Gaze and Wheldon, 1996; Meller, 1997; Hoefnagel et al., 2001 (Boyd et al., 1999 (Boyd et al., , 2001 ). An additional advantage is the built-in`bystander eect' in the form of radiation cross-®re between transfected cells, and cells which have escaped transfection. Clinical application now requires both the transfection of uptake-enhancing genes under the control of tumour-speci®c promoters and the development of vectors suitable for in vivo transfection.
One of the major obstacles to current cancer therapies is the lack of tumour speci®city, which results in toxicity to normal tissues and limitation of therapeutic dose. Targeting gene expression speci®cally to tumour cells is therefore one of the most important goals in cancer gene therapy strategies. Many tissue speci®c promoters have been isolated and utilized in a variety of cancer gene therapy strategies (Nettelbeck et al., 2000) . However a common disadvantage associated with the use of tissue speci®c promoters is that transgene expression also occurs in the normal tissue from which the tumour has evolved. In some cases toxicity and therefore loss of some normal tissue may be acceptable, for example loss of normal prostate cells as a result of utilization of the prostate-speci®c antigen (PSA) promoter. However in many tumours such as brain malignancies, toxicity to normal tissue by utilization of currently available brain speci®c promoters such as glia ®brillary acidic protein (GFAP) promoter to drive expression of toxic transgenes, would result in unacceptable levels of normal tissue toxicity (Vandier et al., 1998 , Eng, 1985 . These limitations may ultimately be overcome by introduction of additional levels of speci®city to the tissue speci®c promoter elements such as coupling tissue speci®c transcription with cell cycle regulation (Nettelbeck et al., 1999) or coupling to other factors speci®c to the physiology of tumours rather than normal cells (Brown and Graccia, 1998) .
Another drawback to utilization of tissue speci®c promoter elements, is their generally inecient activation of transcription (Chen et al., 1998) . One such example is the Von Willebrand factor (VWF) which exhibits a very high degree of endothelial cell speci®city but is a poor activator of transcription (Jahroudi et al., 1994) . Therefore promoter/enhancer elements from genes which are speci®cally expressed or upregulated in tumour cells are attractive. Promoter elements such as the a-fetoprotein promoter (AFP) which under nonpathological conditions, is active speci®cally in the foetal liver, but becomes reactivated in hepatoma cells and the promoter for the gene encoding carcinoembryonal antigen (CEA) which is reactivated in several types of adenocarcinoma have high potential and have been utilized for tumour speci®c expression of transgenes (Kanai et al., 1996; Cao et al., 1999) .
To determine the ability of the human telomerase RNA promoter (hTR) to drive the expression of the NAT gene, we constructed recombinant plasmids containing the NAT gene under the control of dierent promoter elements. A recombinant plasmid which utilized the strong ubiquitous RSV promoter to drive NAT expression was described previously (pNAT) (Boyd et al., 1999 (Boyd et al., , 2001 . To compare this with the activity of the hTR promoter to drive NAT gene expression, a recombinant plasmid containing the hTR promoter and the bovine NAT cDNA (bNAT), was constructed. The NAT cDNA fragment was subcloned into the promoterless pEGFP-1 plasmid (Clontech) from which the EGFP gene had been removed. The 872 bp hTR fragment (Zhao et al., 1998) was then subcloned into the multiple cloning site of the bNAT containing promoterless plasmid and plasmid puri®ca-tions were carried out using Plasmid Maxi Kit (Quiagen, Germany). The resulting plasmids ± hTR/ NAT, a negative control plasmid containing the NAT gene with no promoter element (pr-NAT), and the positive control RSV/PNAT plasmid ± were then transfected into a radiation resistant human glioma cell line (UVW) which does not express NAT (Boyd et al., 1999) utilizing Eecteine transfection reagent (Quiagen, Germany) according to the manufacturer's instructions. Stable transfectants were established by selection of the transfected cells in Geneticin, and once a stable population of UVW cells transfected with each of the plasmids had been established, they were assessed for NAT gene expression by MIBG uptake studies (Figure 1) . UVW cells were seeded at 1610 4 cells per well in six well plates and after 2 days the speci®c uptake of [ 131 I]MIBG in each transfected cell line was measured against desmethylimipramine (DMI) inhibited controls. DMI is a potent inhibitor of noradrenaline transport. Optimal cell densities and methodologies for MIBG uptake studies were as previously determined (Cunningham et al., 1998; Boyd et al., 1999 Boyd et al., , 2001 . (Boyd et al., 1999 (Boyd et al., , 2001 ). This was demonstrated by decreased clonogenic survival or RSV/NAT transfected cells grown as three-dimensional multicellular spheroids rather than two-dimensional monolayers. Consequently, [
131 I]MIBG-induced cell kill was assessed in the various transfected cell lines using both systems. Figure 2 shows the dose-dependent cell kill in monolayers and spheroids derived from cell lines transfected with the plasmids containing the bNAT transgene driven by the dierent promoter constructs. The target cell population (UVW), was maintained and transfected with recombinant plasmids as described previously (Boyd et al., 1999) . Once a population of stably transfected cells had been established by selection in G418, cells were seeded in six well plates at 0.5610 5 cells per well and cultured for 48 h. MIBG incorporation was measured by incubating the cells for 2 h with 7 kBq of [ 131 I]MIBG of speci®c activity 45 ± 65 MBq/mg (Dupont Radiopharmaceutical, Hertfordshire, UK). Non-speci®c uptake was measured in the presence of 1.5 mM desmethylimipramine (DMI) (Sigma-Aldrich, Dorset, UK). After incubation, medium was removed, the cells were washed with PBS and radioactivity was extracted using 10% (w/v) trichloroacetic acid. The activities of the extracts were then measured in a gamma-well counter. Uptake was expressed as counts per minute (c.p.m) per 10 5 cells ]MIBG but the toxic eect of the radiopharmaceutical was much greater when the cells were grown as three-dimensional spheroids. The enhanced cell kill is due to the greater absorption of b-radiation cross-®re in spheroids. Similarly the reduction in survival fraction was much greater in the UVW/hTR/NAT spheroids than monolayers. In both 3-and 2-dimensional cultures, the cell kill was less when NAT was expressed by the hTR promoter rather than the RSV promoter. Sterilization of all clonogens was achieved when the UVW/hTR/NAT spheroids were exposed to 7 MBq/ml [ Spheroids composed of the various transfectants (UVW/RSV/NAT, UVW/hTR/NAT and UVW/pr-NAT), were grown as described and when they were approximately 250 mm diameter, aliquots were removed and incubated with various concentrations of [ 131 I]MIBG in 1 ml of culture medium. After 2 h the spheroids were washed and after addition of fresh medium they were incubated at 378C with shaking for 48 h to allow radiation cross-®re to occur. The spheroids were then disaggregated to a single-cell suspension and seeded out for colony survival in triplicate as described for the monolayer experiments. Figure 2 shows the dose-dependent surviving fractions obtained from the UVW cells grown as monolayers and spheroids transfected with the dierent promoter constructs. With both the RSV and hTR promoter elements, enhanced cell kill was observed at all doses of [ 131 I]MIBG administered when the cells were treated as spheroids rather than monolayers. In monolayers, a dose dependent reduction in colony survival was found for UVW cells transfected with NAT driven by the RSV promoter. Only 14% of these cells survived after treatment with 7 MBq/ml [ 131 I]MIBG. A smaller reduction in surviving fraction was observed when the hTR promoter was utilized to drive expression of NAT, with 40% of cells surviving after administration of 7 MBq/ml [ 131 I]MIBG. However, this result is still indicative of hTR-driven expression of NAT, as 96% of cells transfected with the promoterless NAT transgene survived.
A much greater reduction in surviving fraction was observed when the UVW/RSV/NAT and UVW/hTR/ NAT cells were grown as multicellular tumour spheroids. This is consistent with a contribution from radiation cross-®re to cell kill in these three-dimensional cultures. There was once again little reduction in surviving fraction of spheroids composed of UVW cells transfected with the promoterless plasmid. While the UVW/RSV/NAT spheroids were completely sterilized by 5 MBq/ml [ 131 I]MIBG, 7 MBq/ml was required for sterilization of the spheroids expression NAT under the control of the hTR promoter. While the hTR promoter is expressing NAT at a lower level than the RSV promoter, it appears to be expressing the transporter at sucient levels to allow complete tumour sterilization at a slightly increased dose of [ 131 I]MIBG. Spheroid response to cytotoxic treatment can also be evaluated by the end point of growth delay. This provides an assay of the cytotoxic eects of [
131 I]MIBG in the intact spheroids. In this instance, groups of spheroids were collected and exposed to various concentrations of [ 131 I]MIBG for 2 h. The spheroids were then washed and individual spheroids from each dose group were transferred to individual wells of agar coated 24 well plates. The volumes of individual spheroids were then measured over a period of 4 ± 5 weeks using a microscope coupled to an image analysis system. Figure 3a shows the linear plots of median spheroid volumes over the volumes at day 0, as a function of time after treatment. Con®dence intervals of 95% are shown at two time points only for each dose group to avoid confusion. The growth curves for the UVW/hTR/NAT spheroids became progressively less steep with increasing dose of radiopharmaceutical administered, indicating a dose-related reduction in spheroid regrowth capacity with increasing [
131 I]MIBG. No such reduction in regrowth capacity was apparent in the case of UVW/pr-NAT spheroids, whose growth pro®le was similar to that of untreated control Individual spheroids from each dose group were transferred to separate wells of agar coated 24 well dishes containing 1 ml of fresh medium and incubated at 378C in a 5% CO 2 atmosphere. Growth of the spheroids was measured over a period of 5 weeks by measurement of their cross-sectional area, using a semi-automated image analysis system, coupled to an inverted microscope. From these measurements the median volume of the 24 spheroids from each dose group was calculated. To illustrate the eect of [ 131 I]MIBG concentration on growth delay, we calculated the time taken for spheroids from each dose group to increase their volume threefold (Figure 3b) . Trebling of volumes was attained by un-treated spheroids in 9 days, by spheroids treated with 1 ± 4 MBq/ml [ 131 I]MIBG in 15 ± 18 days, whereas spheroids treated with 5 and 6 MBq/ml did not increase their volume threefold until over 20 days. The spheroids exposed to highest dose tested (7 MBq/ml) did not reach three times their initial volume even after 30 days and a plateau with respect to size increase was observed, indicating eventual loss of proliferative capacity. This provides further evidence that the hTR promoter is active in the UVW glioma cell line and that it is expressing the NAT transgene at sucient levels to allow [
131 I]MIBG uptake and resultant cytotoxicity at higher radionuclide doses.
In summary, we show the potential of a novel system for the treatment of malignant disease. Our data indicate ecient tumour cell kill by treatment with the radiolabelled drug [
131 I]MIBG after expression of the MIBG-speci®c transporter (NAT), controlled by the promoter for the gene encoding the RNA component of telomerase. We are now assessing the protein component promoter (hTERT) for transgene expression in this system. The telomerase promoters not only have the potential for tumour-selective activity, but as we demonstrate, it also acts as a strong inducer of expression. These results are very encouraging for the development of tumour-directed gene therapy.
